PATIENT REPORTED OUTCOMES IN THE DIAGNOSIS AND TREATMENT OF LYMPHOMA
Dr Elizabeth Goodall,
Haematologist and PhD student
Austin Health, Olivia Newton-John Cancer Research Institute & Monash Health, Melbourne, Australia
RESEARCHER PROFILE
Filmed in Melbourne | February 2025
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
After completing her undergraduate degree in Medical Sciences at La Trobe University she went onto complete an Honours degree in malaria research before enrolling in Medicine at Monash University, Gippsland, Victoria in Australia.
Following medical school, she trained at Austin Health and successfully completed both clinical and laboratory haematology programs before moving to a lymphoma clinical trials fellowship at Monash Health. This fellowship provided essential clinical skills and has fostered a life-long interest in improving patient access to trials, finding ways to better select therapies for patients with blood cancers and learning more about the patient’s experience throughout treatment.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
This has led to her PhD on Patient Reported Outcomes (PROs) which will focus on the accurate documentation of the patient experience and learn how best to include this data for future clinical trial design, an essential component of obtaining excellent treatment outcomes. For this work she is the 2025 recipient of the Haematology Society of Australia and New Zealand and the Leukaemia Foundation New Investigator PhD Scholarship which will provide invaluable support throughout the PhD.
-
Identification, characterisation and role of leader cells in ovarian cancer progression
Dr. Maree Bilandzic is a molecular cancer biologist dedicated to advancing the understanding and treatment of ovarian cancer (OC). Her research addresses critical gaps in OC treatment by investigating the mechanisms behind metastasis, chemotherapy resistance, and tumour recurrence. By utilising innovative methodologies and disease-representative models, Dr. Bilandzic has pioneered the identification and characterisation of leader cells (LCs)—a unique, stem-like subpopulation within tumours that plays a crucial role in OC progression.
-
Non-invasive tools for CVD screening and monitoring
Dr Hadi Afsharan is a Research Fellow Cardiovascular Science & Diabetes at the Harry Perkins Institute of Medical Research; is a translational research and innovation fellow in medical technologies at The University of Western Australia, holding dual titles as Translational Fellow and Innovation Fellow within UWA’s Medical School and the FHRI (Future Health Research and Innovation) program.
-
Lymphoma, Myeloma and Genomics
Professor Dipti Talaulikar is a clinical and laboratory haematologist with expertise in genomics, working at Canberra Health Services, and Professor at ANU. She has a clinical and research interest in lymphoma, myeloma and genomics, and has authored close to 100 peer reviewed papers, including several clinical guidelines that have had a significant impact on clinical practice.
